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Background and Objectives. Subjects with blood type
O have lower concentration of von Willebrand factor (VWF)
than those with type A, B or AB. Since we recently
observed that laboratory signs of marked hypercoagula-
bility are compatible with health and longevity in Italian
centenarians, we determined VWF and blood groups in
healthy centenarians to see whether levels of this mark-
er of endothelial perturbation were altered and whether
its correlation with blood groups was similar to that
among the general population. 
Design and Methods. In 74 centenarians and in 110
controls (55<45 years old; 55>45 years old), we studied
VWF antigen (VWF:Ag), ristocetin co-factor activity
(VWF:Rco), multimeric pattern of VWF and cleaving pro-
tease (VWF:CP), and plasmin-antiplasmin complexes
(PAP).
Results. The levels of VWF:Ag and VWF:Rco in cente-
narians were significantly higher than in controls without
significant difference between  blood group O or non-O.
Fifty-one percent of centenarians have a reduction of the
relative proportion of high molecular weight multimers
(HMV); furthermore VWF:CP was lower and PAP signifi-
cantly higher than in young controls.
Interpretation and Conclusions. The loss of large VWF
multimers in 51% of centenarians could depend on degra-
dation protease(s) in the circulation. VWF, a well-known
independent predictor of atherothrombotic disease, was
increased in centenarians, independently of the blood
group, confirming the previous results of a state of hyper-
coagulability. The finding that the VWF:CP levels are low
when VWF levels are high in centenarians could be a corol-
lary of the previous described paradox of successful
aging, adding another marker of increased risk of athe-
rothrombosis to the scenario.
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Centenarians have a state of hypercoagulabilitywith striking signs of high coagulation enzymeactivity, enhanced formation of fibrin and sec-
ondary high hyperfibrinolysis.1,2
It is of interest that centenarians have a significant-
ly higher frequency than young individuals of the high-
risk 4G allele of the PAI-1 -675 (4G/5G) polymorphism,3
mutant factor V (Arg506Gln)4 and prothrombin gene
G20210A mutation.5 Nevertheless, they have aged suc-
cessfully and escaped major thrombotic diseases. The
elevation of activated factor VII (FVIIa) concentration in
centenarians could be the result of enhanced expression
and availability of tissue factor. While tissue factor is
usually not expressed in intact vasculature, high levels
of FVIIa could be an expression of endothelial cell per-
turbation. von Willebrand factor (VWF) is the major
adhesive protein, circulating in the plasma as a series
of heterogeneous multimers of  molecular weight 400
to 2000 Kdaltons; only the highly polymeric forms are
hemostatically active.6 VWF is involved in the initiation
of platelet adhesion to the damaged vascular wall7 and
is a well-known marker of endothelial perturbation.8,9,10
In addition, VWF is an independent predictor, together
with fibrinogen and tPA antigen, of myocardial infarc-
tion or sudden cardiac death.11 Elevated circulating lev-
els of VWF may be associated with an increased risk of
death following stroke.12 The ABO blood group type is
associated with the plasma concentration of VWF anti-
gen (VWF:Ag)13,14 i.e., concentrations are higher in indi-
viduals of non-O blood groups than in those of blood
group O. Higher risks of coronary heart disease, ather-
osclerosis, and venous thromboembolism have been
shown in individuals with non-O blood groups.15,16 Pro-
teolytic cleavage of VWF takes place in the circulating
blood of healthy subjects.17 The hemostatically active
large VWF multimers are degraded to smaller less active
forms. There is little knowledge on the behavior of pro-
teases in longevity, but is seems than the protease lev-
el is usually low when VWF is high: thus the contribu-
tion of the protease to the atherothrombotic risk of
VWF could be explored.
We measured VWF:Ag levels and determined the blood
groups in 74 healthy centenarians to see whether the
levels of this marker of endothelial damage were higher
and the correlation with blood groups was similar to
that among the general population. In the same patients
VWF:Rco was determined to see whether corresponding
levels are altered in comparison with levels of VWF:Ag.
We also performed VWF multimeric analysis of VWF by
SDS-agarose discontinuous gel electrophoresis; the rel-
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ative proportion of high molecular weight (HMV)
multimers was calculated by scanning the autora-
diography with a densitometer. VWF:CP levels were
measured as previously described. Plasmin-antiplas-
min complex (an index of plasmin formation and
neutralization) was also measured.
Design and Methods
Subjects
A total of 184 individuals were studied; 74 were
cases more than 100 years old and 110 were con-
trols less than 100 years old. Approval for these
studies was obtained from  the Institutional Review
Board of the University of Milan and informed con-
sent was obtained according to the Declaration  of
Helsinki. Centenarians (age range 100 to 107 years;
18 men and 56 women)  were ambulatory, self-
sufficient and lived in their homes in metropolitan
communities of Northern Italy (Milan, Modena).
They were  chosen on the basis of the strict crite-
ria set  by the Senieur Protocol.18 Chronic disorders
such as infection, inflammation, malignancy,
dementia, diabetes, cardiovascular, renal and liver
disease were causes for exclusion. An electrocar-
diogram and hemocytometry were performed and
erythrocyte sedimentation rate and plasma con-
centrations of glucose, sodium, potassium, albu-
min, alkaline phosphatase, aminotransferases, urea
and creatinine were measured. Centenarians with
values outside the 2.5 and 97.5 percentiles of the
reference values of these measurements were
excluded. Controls (n=110, aged 21 to 86, 49 men
and 61 women) were chosen to make up two
groups of equal size: younger controls, aged < 45
years, who were blood donors or hospital staff
members, and older controls, aged > 45 years. On
the basis of history and physical examination , none
of these control subjects had any of the conditions
taken as causes for exclusion for the group of
healthy centenarians.
Blood sampling and processing
Venous blood was obtained between 8:00 and
10:00 a.m. from the antecubital veins by the two-
syringe technique, using 19-gauge needles. After
the first 4 mL of blood had been discarded, samples
were collected directly into vacutainers containing
Na2-EDTA. All blood specimens were centrifuged at
4°C for 20 min at 2000×g and platelet-poor plas-
ma was stored at -80°C until assayed within 2
months. Blood groups were determined by the
courtesy of Dr. Moroni at the S. Paolo Hospital,
Blood Bank Center, Milan, Italy.
Assays
VWF:Ag was assayed by ELISA using monoclon-
al antibodies, as previously described.19 Pooled nor-
mal plasma calibrated against the WHO standard
for VWF (97/586) was used as a reference. The
technicians were at all times unaware of whether
samples came from patients or controls. VWF:Rco
was performed with a modification of Macfarlane’s
method.20 VWF multimeric analysis of VWF was
performed by SDS-agarose discontinuous gel elec-
trophoresis; the relative proportion of HMV multi-
mers was calculated by scanning the autoradiog-
raphy with a densitometer with a modification of
Ruggeri’s method.6 VWF cleaving proteases assay
was performed using a previously described
enzyme immunoassay.17 Plasmin-antiplasmin com-
plex (PAP) was measured by an ELISA (Behringw-
erke, Marburg, Germany).
Statistical analysis
The values obtained in controls and  centenari-
ans were analyzed  after  transformation into log-
arithms, but for descriptive purposes are given as
geometric means and 95% confidence intervals.
Comparisons between the groups were made by
analysis of variance and between-group differ-
ences assessed with the Sheffé test.
Results
VWF:Ag and VWF:Rco levels are higher in cente-
narians than in the controls, both older and younger.
The distribution of blood types among the controls
mimics that in the general population (35% type O,
65% type non-O), whereas 43% of the centenarians
had blood type O, and 57% had type non-O. Figure
1 shows that the correlation between VWF:Ag lev-
els and blood types agrees with the well known fact
that individuals with blood type O have lower mean
concentrations of VWF:Ag than those with blood
type non-O: (p<0.0006 and p<0.0001) (Figure 1).
Figure 1. von Willebrand factor (U/dL) related to blood
groups in younger, older, and centenarian individuals.
Closed circles represent blood group type O, open circles
type non-O.
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The levels of VWF:Rco corresponded to antigen lev-
els (Table 1) and were well-correlated (r = 0.87,
p=0.0001). In contrast, centenarians with blood
group O and those with non-O had equally high lev-
els of VWF:Ag. Using a cut-off of 17%, established
in our laboratory database from younger and older
subjects, we observed that 51% of the centenarians
had a reduction of the relative proportion of HMW
multimers as compared to that in younger controls,
and in only 25% of older controls was a similar mul-
timeric pattern present (Table 2, Figure 2). In 62%
of centenarians the VWF:CP was lower than in
young controls: 76% (50-97%) vs. 105% (52-175%)
(p=0.01). There was a statistically significant inverse
correlation between the proteases, VWF:Ag (r = -
040) and VWF:Rco (r = -0.39). PAP were much high-
er in centenarians than in controls: 858 (768-928
ng/mL), compared to 330 (315-400 ng/mL) and 285
(253-321 ng/mL) in old and young controls, respec-
tively.
Discussion
The level of VWF:Ag is extremely high in cente-
narians. The predominant site of VWF synthesis is
the vascular endothelium,21 which is the major
source of plasma VWF in vivo.22 In addition to this
continuous release of VWF, rapid secretion of pre-
formed VWF, localized in intracellular storage
organelles called Weibel-Palade bodies23,24 can be
provoked in vivo and in vitro by a number of agents.
Paleolog et al. demonstrated that cytokines have no
direct effects on VWF release from cultured vascu-
lar endothelial cells but can significantly modulate
its acute secretion  in response to thrombin.25 It
has been shown that in centenarians there is a
marked increase in the number of circulating acti-
vated T-lymphocytes (CD3 and HLA-DR positive)
which may interact with endothelial cells in
response to thrombin.26 Furthermore, in centenar-
ians increased thrombin generation was expressed
as high levels of FVIIa correlated with factor X and
factor IX activation peptides.1
The underlying mechanism of the effect of the
blood group on VWF might be related to differ-
ences in the processing, release, or catabolism of
VWF in people with different blood groups.13 Evi-
dence for these differences includes the finding of
different oligosaccharides in the blood group A, B,
and O structures of human VWF,27,28 and the find-
Table 1. Geometric means (95% confidence intervals) of
von Willebrand factor antigen and VWF:Rco levels (U/dL) in
younger, older and centenarian individuals, related to blood
group.
VWF:Ag (U/dL) vWF:Ag (U/dL) p VWF:Rco (U/dL) VWF:Rco (U/dL) p
O non-O O non-O
Younger 77 115 0.0006 80 112 0.0017
controls (67-91) (100-132) (60-107) (76-164)
(n=55)
Older 99 152 0.0001 98 151 0.0003
controls (84-117) (133-174) (67-145) (100-228)
(n=55)
Centenarians 245 285 NS 230 251 NS
(n=74) (215-279) (251-325) (159-332) (174-360)
Table 2. Relative proportion of high molecular weight VWF
multimers in centenarians and controls.
Cut-off%
Range % ≤17 >17 
Younger 18-28 0 100 
Older 15-20 25 75 
Centenarians 10-20- 51 49
Figure 2. Multimeric structure of VWF protein: 1 normal
plasma sample, 2 centenarians with normal pattern, 3 and
4 centenarians with a reduction in the relative proportion of
high molecular weight multimers.
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ing that antiserum against blood groups A and B
reacts only with VWF immunoprecipitate from
individuals with the appropriate blood group. We
found no significant differences in VWF:Ag levels
between centenarians of blood group O and non-
O. In order to investigate the possible mechanisms
responsible for the decrease of VWF:Ag in people
with blood group O, Gill et al.29 studied  VWF:Ag
and VWF antigen II (VW AgII) in blood donors. Nei-
ther VWF:Ag nor VW AgII was different in secretors
of H substance, as determined by the Lewis blood
group, in either group O or non-O individuals. The
cleavage of pro-VWF into mature VWF and its
propolypeptide, VW AgII, is thought to occur in the
storage granule and both are thought to be
released into plasma simultaneously. Since previ-
ous studies of VW AgII in type II von Willebrand’s
disease suggest that VW AgII may reflect the rate
of VWF synthesis, the findings of decreased
VWF:Ag but not of VW AgII in normal group O indi-
viduals  may be due to a more rapid clearance of
VWF from plasma. We can surmise that centenar-
ians, who had equally high levels of VWF:Ag
whether they had group O blood or not, could have
slower clearance of VWF from the circulation.
The loss of large VWF multimers in 51% of cen-
tenarians could depend on degradation protease(s)
in the circulation, as suggested by very high PAP
levels. The finding that the VWF:CP levels are low
when VWF levels are high in centenarians could be
a corollary of the previously described paradox of
successful aging, adding another marker of
increased risk of atherothrombosis to the scenario.
The concentration of plasmin-antiplasmin com-
plex is much higher in centenarians than in con-
trols (858 ng/mL compared to 330 ng/mL and
285ng/ml in older and younger controls, respec-
tively, p<0.01). The presence of a modified form of
VWF in centenarians could counteract the appar-
ently unfavorable hemostasis profile due to the
high levels of VWF:Ag. Nevertheless, we have also
demonstrated this paradoxical marked hypercoag-
ulability by genetic markers.3,4,5 Furthermore, it has
been shown that most centenarians have high
serum levels of lipoprotein(a), low HDL cholesterol
and relatively high tryglicerides levels, which
together are considered to be strong risk factors for
coronary artery disease.30 Thus , a long life is com-
patible with the possession of several high-risk
alleles and high concentrations of well-known car-
diovascular risk factors.
Parameters considered risk factors for the ather-
osclerotic vascular diseases in young people may
lose their biological significance in advanced age
and assume a different role.
Our data about the hemostasis profile of cente-
narians once again emphasize the need for a mul-
tidisciplinary approach if we wish to understand
the mechanisms of successful aging.
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What is already known on this topic
Although centenarians show a state of hyperco-
agulability, they have aged successfully and escaped
major thrombotic diseases.
What this study adds
This study shows that the plasma levels of von
Willebrand antigen are significantly higher in cente-
narians, thus confirming the above paradox of suc-
cessful aging.
